论文部分内容阅读
在刚刚闭幕的第16届国际艾滋病大会上,美国默克公司披露,他们正在研制一种全新的艾滋病治疗药物——整合酶抑制剂,根据该公司公布的该药的临床试验数据,新的药物可以快速减少患者血液中艾滋病病毒的数量。整合酶抑制剂属于新类型的艾滋病治疗药物,它的工作机理在于阻断一种酶,这种酶能使病毒将其遗传物质与宿主细胞的 DNA结合起来并进行自我复制。随着越来越多的患者对目前标准治疗方法产生耐药性,整合酶抑制剂为治疗艾滋病患者带来了希望。这种新药的化合物代号为“MK-0518”。科研人员目前正在对198名艾滋病患者进行该药的临床试验。这些患者在感染病毒后没有接受其他药物的治疗。治疗初期,每位患者的血液中每毫升至少含有5000个可复制的病毒,同时具有较低数量的易受HIV 病毒攻击的免疫系统 CD4细胞,细胞数平均为每微升271个至314个。6个月后的临床试验报告显示,有85%至95%服用整
At the just concluded 16th International AIDS Conference, Merck revealed that they are developing a new HIV drug - integrase inhibitors, according to the company’s clinical trial data released by the drug, the new drug Can rapidly reduce the amount of HIV in the blood of patients. Integrase inhibitors are part of a new class of HIV therapies that work by blocking an enzyme that allows the virus to bind its genetic material to the host cell’s DNA and replicate itself. Integrase inhibitors offer promising treatment for AIDS patients as more and more patients become resistant to the current standard of care. The compound for this new drug is codenamed “MK-0518”. Researchers are currently on 198 AIDS patients in the clinical trials of the drug. These patients did not receive any other medication after they had been infected with the virus. At the start of treatment, each patient contained at least 5,000 replicable viruses per milliliter of blood, as well as a lower number of CD4-vulnerable immune cell systems, with an average of 271 to 314 cells per microliter. A clinical trial report after 6 months showed that 85% to 95% of patients took the whole body